Keeping you in prayers that your team can find another protocol that can keep you comfortable and stable, with minimal side effects. Gentle hugs!
August 13
It's really common for treatments to stop working over time, and it makes sense to explore what's next. Many MyBCTeam members have shared positive experiences with Enhertu, and the clinical research behind it is genuinely encouraging.
A recent phase 3 trial looked at Enhertu combined with Perjeta (pertuzumab) for Show Full Answer
It's really common for treatments to stop working over time, and it makes sense to explore what's next. Many MyBCTeam members have shared positive experiences with Enhertu, and the clinical research behind it is genuinely encouraging.
A recent phase 3 trial looked at Enhertu combined with Perjeta (pertuzumab) for HER2-positive metastatic breast cancer. Here are some highlights:
- Patients had a 44% lower chance of their cancer getting worse or of dying compared to the standard treatment
- Cancer did not progress for about 40.7 months on average
- Tumors shrank in about 85% of patients
- Tumors disappeared completely in 15% of patients — nearly double the rate of the comparison group It's worth knowing about some side effects to watch for with Enhertu:
- Nausea, vomiting, and constipation are more common
- About 12% of patients developed a lung condition called interstitial lung disease, though most cases were mild
These results are exciting enough that researchers believe this combination could become a new standard first-line treatment. Talking with your oncologist about whether Enhertu is right for your specific situation — including your pleural and liver involvement — is a great next step.
August 13
Join
Your Privacy Choices
